On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Cerecor, Inc. (CERC) and Aspire Capital Fund Enter into Stock Purchase Agreement worth $15 Million

Cerecor, Inc. (NASDAQ: CERC) and Aspire Capital Fund, LLC (“Aspire”) have entered into common stock purchase and registration rights agreements worth $15 million. Cerecor is a clinical-stage biopharmaceutical company specializing in developing drugs that can help people with neurological and psychiatric disorders. Aspire is an institutional investor organization based in Chicago.

The agreement covers Aspire’s purchase of $1 million worth of Cerecor common stocks at a rate of $4 per share. This initial purchase is a 4% premium over the September 8 closing stock price of $3.86. The remaining $14 million will be paid by Aspire if Cerecor decides to sell the remaining shares. If and when Cerecor decides to sell shares to Aspire, this can only be done once the registration has been filed and the U.S Securities and Exchange Commission has deemed it effective. Cerecor has agreed to file the registration.

The remaining $14 million worth of shares will be sold to Aspire over a period of two and a half years. Cerecor will be in charge of when and for how much these sales will be made. The prices of any sales made in the future will be calculated according to market prices during each sale. The money raised from this agreement will be used to move forward in research and development, as well as for working capital and business development.

In a recent news release, Dr. Uli Hacksell, president and CEO of Cerecor, stated, “The Agreement with Aspire facilitates the continued advancement of our portfolio of novel product candidates. This funding agreement also provides Cerecor with additional financial flexibility heading into 2017.”

Steven G. Martin, managing member of Aspire Capital said that the company is happy to be entering into the agreement with Cerecor, as it has an experienced management team and a favorable neurological and psychiatric drug pipeline. He commented, “We are looking forward to Phase 2 clinical data for CERC-301 and CERC-501 in the relatively near future. We believe this Agreement will help provide the Company with a flexible and efficient source of capital to advance these very exciting development programs.”

For more information, visit www.Cerecor.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217